[D1-1-1]LC/MS基礎講座～バイオマーカー定量時の留意点を中心に～
*Koji Arai1(1. LSI Medience Corporation)
14th JBF Symposium
Mar 1 - Mar 3, 2023タワーホール船堀/Web配信(ハイブリッド開催)
You can search for presentations in this event.
Search
14th JBF Symposium
Mar 1 - Mar 3, 2023タワーホール船堀/Web配信(ハイブリッド開催)
You can search for presentations in this event.
SearchSearch Results(70)
[D1-1-2]LBAにおけるADA分析法開発基礎講座
*Tatsuki Nomura1(1. Shin Nippon Biomedical Laboratories, Ltd.)
[D1-2-1]Welcome Greetings
*Tomoko Arakawa1, Yumi Nishiguchi2(1. The 14th JBF Symposium Executive Committee Chair, Pfizer R&D Japan, 2. The 14th JBF Symposium Executive Committee Vice Chair, CMIC Pharma Science Co. Ltd)
[D1-2-2]Opening Remarks for 14th JBF Symposium
*Yoshiro Saito1(1. National Institute of Health Sciences)
[D1-3-1]Introduction and Overview of ICH M10 Guideline
*Akiko Ishii-Watabe1, Yoshiro Saito1(1. National Institute of Health Sciences)
[D1-3-2]ICH-M10: JBF Workshop Report
*Makoto Takahashi1(1. Japan Bioanalysis Forum (Daiichi Sankyo Co., Ltd.))
[D1-3-3]AAPS Feedback and Discussions Regarding ICH M10 Guidance and Implementation
*Chad J Briscoe1, Stephanie Cape2(1. Celerion on behalf of AAPS, 2. LabCorp)
[D1-3-4]Feedback from the EBF Workshop on Harmonised Implementation of the ICH M10 Guideline
*Philip Timmerman1(1. European Bioanalysis Forum)
[D1-4]JBF-JPMA collaboration session
Questionnaire Survey on Development Strategy of Drug Concentration Analysis and Analytical Methods in Biological Samples
*Kairi Nakamura1, *Miyuki Tamura1, Shinya Hosaka1, Masayo Hashimoto1, Makoto Niwa1, Kazuyo Yokohata1, Takafumi Muto1, Ayako Suzuki1, Seiji Tanaka1, Takashige Okayama1, Shiho Suruki1, Takanori Ikeda1, Mutsumi Suzuki1(1. Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association)
[D1-5-1]Application of LIMS in the Field of Bioanalysis
*Kazuo Tokuda1, Kazuhiro Nishimiya1, Takashi Miyayama1, Kimio Terao1(1. Chugai Pharmaceutical Co., Ltd.)
[D1-5-2]Current Utilization Status and Future Perspective of LIMS in SNBL Bioanalysis Operations
*Katsunori Ieki1(1. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.)
[D1-5-3]Digitalization and Automation for Bioanalysis
*Katsutomo Hata1(1. Shionogi & Co., Ltd.)
[2DGP001]Bioanalysis using columns other than ODS (DG2022-55)
*Ryotaro Yagi1, *Misato Noguch2, *Masayoshi Mizuochi3, *Shiori Miyawaki4(1. Toray Industries, Inc., 2. EA Pharma Co., Ltd., 3. CMIC Pharma Science Co., Ltd., 4. Shin Nippon Biomedical Laboratories, Ltd.)
[2DGP002]Digital transformation in the field of bioanalysis (DG2022-57)
*Yoshitaka Hashimoto1, *Ayaka Kondo2, *Tomoka Shimada3, *Shoko Yamamoto4(1. ONO Pharmaceutical Co., Ltd., 2. SHIONOGI & CO., LTD., 3. Shionogi TechnoAdvance Research & Co., Ltd., 4. Shin Nippon Biomedical Laboratories, Ltd.)
[2P001]Development of quantitative mass spectrometry imaging(q-MSI) of dopamine using simple mimetic animal tissue spots.
*Erika Nagano1, Kazuki Odake1, Shuichi Shimma1,2(1. Research and Development Department, Miruion Corporation, 2. Department of Biotechnology, Graduate School of Engineering, Osaka University)
[2P002]Development of a simple method for exosomal miRNA expression using a small amount of human serum sample
*Tatsuki Yamamoto1, Masaki Ishigai1(1. Pharmaron Japan LLC)
[2P003]Development of analytical method of racemization and isomerization of aspartic acid in amyloid β using a chiral resolution labeling reagent D-FDLDA
*Makoto Ozaki1, Motoshi Shimotsuma1, Takefumi Kuranaga2, Hideaki Kakeya2, Tsunehisa Hirose1(1. Nacalai Tesque, Inc., 2. Department of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University)
[2P004]Assay Method Development for the Determination of Soluble Delta-like Protein 3 (sDLL3) in Human Serum by ELISA
*Chisato Yanagisawa1, Masanobu Nishidate2, Kayo Aida1, Takashi Miyayama2(1. Chugai Research Institute for Medical Science, Inc., 2. Chugai Pharmaceutical Co., Ltd.)
[2P005]Development of clot biopsy as a novel inflammatory marker search method
*Yasuhiro Yoshida1(1. University of Occupational and Environmental Health, Japan)
[2P006]Development of antibody bridging assay for immunogenicity testing of oligonucleotide therapeutics using PALSAR signal amplification
*Tetsuo Sekino1, Akane Omori1, Maya Iwata1, Koichi Shibusawa1, Akira Ideno1(1. Sekisui Medical Co., LTD.)
[2P007]PK/PD analysis of antibody drugs based on target engagement measurement using immunoaffinity LC-MS
*Yutaro Hoshi1, Yuki Oda1, Junji Komaba1, Yoshiyuki Yamaura1(1. Pharmacokinetic Research, ONO Pharmaceutical Co., Ltd.)
[2P008]Evaluation of the analytical performance of anti-SARS-CoV-2 neutralizing antibody test kits
*Hiroko Shibata1, Kazuko Nishimura1, Takuya Maeda2, Kouichi Morita3, Yoshiro Saito4, Akiko Ishii-Watabe1(1. Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 2. Department of Clinical Laboratory, Saitama Medical University Hospital, 3. Institute of Tropical Medicine, Nagasaki University, 4. Division of Medicinal Science, National Institute of Health Sciences)
[2P009]Automated Data Analysis Workflow Enabling Unbiased New Peak Detection for MAM Implementations
*Naohiko Heida1, Peter Haberl2, Arnd Brandenburg3(1. Genedata KK, 2. Genedata GmbH, 3. Genedata AG)
[2P010]Quantitative analysis of oligonucleotide therapeutics by LC-MS/MS using automated purification system applying hybridization and comparison with quantitative analysis by conventional methods
*Masayoshi Mizuochi1, Hayashi Yoshiharu1, Hanari Suguru1, Danno Noriyuki1, Nishiguchi Yumi1, Koyama Aki1(1. CMIC Pharma Science Co.,Ltd)
[2P011]Low Cost Entry for Sample preparation Automation
*Masatomo Goto1, Tatsunari Yoshida1(1. Biotage Japan, Ltd.)
[D2-1-1]A Case Study for Visualizing Oligonucleotide Therapeutics by using Imaging Mass Spectrometry
*Hiroaki Aikawa 1, Hiroki Hisasue 2, Hideyuki Watanabe 2, Norifumi Sakai 2, Shin-ichiro Nitta 1, Hidefumi Kaji 1, Takeshi Kanno 2, Tsuyoshi Higuchi 2, Tomoharu Osada 1, Ryoya Goda 3, Yuchen Sun 4, Kosuke Saito 4, Yoshiro Saito 4, Koudou Miura 1(1. LSI Medience Corporation , 2. LSIM Safety Institute Corporation , 3. Daiichi Sankyo Co., Ltd. , 4. National Institute of Health Sciences )
[D2-1-2]Points to Note in Bioanalysis of Therapeutic Oligonucleotides by Ion-Pair LC-MS/MS
*Suguru Fukuda 1, Kazunari Hirowatari 1, Katsunori Ieki 1(1. Shin Nippon Biomedical Laboratories, Ltd． )
[D2-1-3]Comparison of Bioanalytical Methods for the Oligonucleotide Therapeutics
*Yoshiharu Hayashi 1, Suguru Hanari 1, Masayoshi Mizuochi 1, Nobuhiro Suzuki 1, Noriyuki Danno 1, Yumi Nishiguchi 1, Aki Koyama 1(1. CMIC Pharma Science Co., Ltd. )
[D2-1-4]Bioanalysis of Oligonucleotides: Challenges and Solutions
*Eric Thomas 1, Bingbing Wang 1, Brendan Powers 1(1. Labcorp Drug Development )
[D2-2-1]Development of Biomarker of Microglial Activation
*Tatsuya Ikehara 1, Tatsuya Yanagawa 1, Sosuke Yoneda 1(1. Shionogi & CO., LTD.)
[D2-2-2]Diversity of Biomarker Analysis - Case of qPCR, FCM and IHC -
*Makoto Yamazaki 1, Tomoya Akashi 1, Tadashi Endo 1, Masayoshi Saito 1, Hiroyuki Shimizu 1(1. Mitsubishi Tanabe Pharma Corporation )
[D2-2-3]Utilization of Sphingolipids as Translational Biomarkers
*Yohei Kosugi 1, Shin-ichi Matsumoto 1, Sho Sato 1, Kentaro Otake 2(1. Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited , 2. Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited )
[D2-2-4]Strategy to Select Fit-For-Purpose Bioanalytical Methods for Successful Measurement of Translational Biomarkers
*Motohiko Morihara 1(1. Ono Pharmaceutical Co., Ltd. )
[D2-3]Considerations When Implementing a Computerized System -Based on the Description in the OECD GLP Data Integrity Guidance-
*Tomoharu Shimokawa 1,2(1. Toray Research Center, Inc. , 2. Japan Society of Quality Assurance GLP Division )
[D2-4-1]Immunogenicity Profile of the Port Delivery System with Ranibizumab in Patients with nAMD
*Mauricio Maia 1, John Lowe 1, Steven Blotner 2, Galin Spicer 3, Natasha Singh 4, Shweta Vadhavkar 5, Derrick Kaufman 6, Ihsan Nijem 1, Weili Yan 1, Han Ting Ding 5, Matts Kaagedal 5, Giulio Barteselli 7, Keshwin Sharma 1, Katie Maass 5(1. Bioanalytical Sciences Department, Genentech/Roche , 2. Data & Statistical Sciences OMNI, Genentech/Roche , 3. Ophthalmology/US Medical Affairs, Genentech/Roche , 4. Clinical Safety Department, Genentech/Roche , 5. Clinical Pharmacology Department, Genentech/Roche , 6. Data & Statistical Science, Genentech/Roche , 7. Ophthalmology, Genentech/Roche )
[D2-4-2]Feedback from the EBF Workshop on Points to Consider on Cut Points for Immunogenicity
*Joanne Goodman1(1. European Bioanalysis Forum)
[D2-L-1]Extracellular Vesicles & Circulating Tumor Cells: Recent Studies on Liquid Biopsy Techniques for Biomarker Detection
*Tomoko Ichibangase1(1. Sumika Chemical Analysis Service, Ltd.)
[D2-tDG-1]t-DG
[D2-L-2]Introducing Sciex's Mass Spectrometer Technology, the Next Level Quantitative/Quantitative Analysis
*Ushio Takeda1(1. SCIEX)
[D2-tDG-2]t-DG
[D2-L-3]The Latest LC-MSMS Systems and Informatics to Achieve Reliable Bioanalysis of Middle-Molecule Drugs
*Maki Terasaki1(1. Nihon Waters K.K.)
[D2-L-4]Application of the timsTOF Series to Biopharmaceutical Analysis
*Taiga Arai1(1. Bruker Japan K.K.)
[D2-tDG-3]t-DG
[3DGP001]Lifecycle management of ligand binding assays (DG2022-56)
*Suguru Hanari1, *Ryuichiro Kimura2, *Tomoko Kojima3, *Hiroyuki Shimizu4, *Yukako Taniguchi5, *Kosuke Fukuda6(1. CMIC Pharma Science Co., Ltd., 2. Shionogi TechnoAdvance Research Co., Ltd., 3. Sunplanet Co., Ltd., 4. Mitsubishi Tanabe Pharma Corporation, 5. Shin Nippon Biomedical Laboratories, Ltd., 6. Sumitomo Pharma Co., Ltd.)
[3DGP002]Effective instruction for the bioanalyst career path (DG2022-58)
*Shinsuke Uchihashi 1, *Momoko Eda 2, *Tadashi Endo 3, *Yuki Kishino 4, *Kei Yoshida 5, *Yuji Rikitake 6, *Makoto Niwa 7(1. Maruho co., Ltd. , 2. Pfizer R&D Japan G.K. , 3. Mitsubishi Tanabe Pharma Corporation , 4. Daiichi Sankyo Co., Ltd. , 5. Chugai Pharmaceutical Co., Ltd. , 6. Shin Nippon Biomedical Laboratories, Ltd. , 7. Nippon Shinyaku Co., Ltd. )
[3P001]Determination of drug concentrations in biological samples using automated ELISA system
*Fumie Sawamura1, Masumi Yano1, Masanobu Nishidate2, Kazuhiro Nishimiya2, Kayo Aida1, Takashi Miyayama2(1. Chugai Research Institute for Medical Science, Inc., 2. Chugai Pharmaceutical Co., Ltd.)
[3P002]Multilaboratory validation of immunoaffinity liquid chromatography/mass spectrometry based glucagon-like peptide-1 assay
*Rika Ishikawa1, Kosuke Saito1, Hidehisa Tachiki2, Ryoya Goda3, Koji Arai4, Hisao Shimizu5, Tomohiro Andou6, Kentaro Takahara7, Hitoshi Uchiyama2, Shin-ichiro Nitta4, Masaaki Kakehi5, Kozo Hayashi6, Naohiro Katagiri2, Keiko Kojima4, Hisashi Fujita5, Kazuhiro Tsuchinaga6, Yoshiro Saito1(1. National Institute of Health Sciences, 2. Towa Pharmaceutical Co., LTD., 3. Daiichi Sankyo Company, 4. LSI Medience Corporation, 5. Takeda Pharmaceutical Company, Limited, 6. Axcelead Drug Discovery Partners, Inc., 7. Thermo Fisher Scientific K.K.)
[3P003]Evaluation of pharmacokinetics in longitudinal blood collection in mice applying "ultra-trace" sampling technique exceeding microsampling and "ultra-sensitive" LC-MS/MS instrumentation
*Emiko Hirose1, Yoshie Ninomiya1(1. Research Division, Toray Research Center, Inc. )
[3P004]Examination of Pretreatment Methods by Ion Exchange Solid Phase Extraction for Therapeutic Oligonucleotides.
*Takuma Kamiya1, Shiori Miyawaki1, Kouichiro Hori1, Suguru Fukuda1, Kazunari Hirowatari1, Katsunori Ieki1(1. Shin Nippon Biomedical Laboratories, Ltd.)
[3P005]Profiling polysorbate 80 components using comprehensive liquid chromatography-tandem mass spectrometry analysis
*Yutaka Konya1, Ryosuke Ochiai1, Satoshi Fujiwara1, Kazushige Tsujino1, Takeshi Okumura1(1. Shimadzu Techno-Research, Inc. Pharmaceuticals and Life Sciences Division)
70 results ( 1 - 50 )
- 1